AIM: To systematically assess the association between sex hormone-binding globulin(SHBG)(TAAAA)n and androgen receptor(AR)(CAG)n polymorphisms and polycystic ovarian syndrome(PCOS) risk.METHODS: We searched MEDLINE(Pu...AIM: To systematically assess the association between sex hormone-binding globulin(SHBG)(TAAAA)n and androgen receptor(AR)(CAG)n polymorphisms and polycystic ovarian syndrome(PCOS) risk.METHODS: We searched MEDLINE(PubM ed), EMBASE and Web of Science database from inception to May2014. To avoid missing any additional studies, we looked through all the references of relevant articles. Case-control studies concerning the(CAG)n variants in the AR gene or the(TAAAA)n polymorphism in the SHBG gene in PCOS patients were included. Five studies regarding the(TAAAA)n polymorphism in the SHBG gene and 14 studies regarding the(CAG)n polymorphism in the AR gene met our criteria. Odd ratio(OR) and weighted mean difference(WMD) were selected as the effect size measurements to evaluate the influence of the(TAAAA)n polymorphism and(CAG)n variants on PCOS risk. Begg's test was used for the evaluation of publication bias.RESULTS: With respect to the relationship between the(TAAAA)n polymorphism and PCOS risk, the statistical results showed that there was no significant difference between PCOS patients and controls in the alleles of TAAAA(S: OR = 0.91, 95%CI: 0.78-1.05; L: OR = 1.10, 95%CI: 0.95-1.27). Subgroup analyses of the combination of alleles indicated similar results(shortshort: OR = 0.87, 95%CI: 0.66-1.14; short-long: OR = 1.12, 95%CI: 0.86-1.46; long-long: OR = 1.03, 95%CI: 0.72-1.47). As for the relationship between the(CAG)n polymorphism and PCOS risk, we found no association between CAG repeat variants and PCOS risk(WDM = 0.03, 95%CI:-0.13-0.08). Subgroup analyses by race and diagnosis criteria indicated the same results(Asian: WMD =-0.03, 95%CI:-0.14-0.07; Caucasian: WMD =-0.02, 95%CI:-0.24-0.21; the criteria of Rotterdam: WMD = 0.01, 95%CI:-0.01-0.03). CONCLUSION: There is no association between(TAAAA)n polymorphism in SHBG gene,(CAG)n repeat variants in AR gene and PCOS.展开更多
文摘AIM: To systematically assess the association between sex hormone-binding globulin(SHBG)(TAAAA)n and androgen receptor(AR)(CAG)n polymorphisms and polycystic ovarian syndrome(PCOS) risk.METHODS: We searched MEDLINE(PubM ed), EMBASE and Web of Science database from inception to May2014. To avoid missing any additional studies, we looked through all the references of relevant articles. Case-control studies concerning the(CAG)n variants in the AR gene or the(TAAAA)n polymorphism in the SHBG gene in PCOS patients were included. Five studies regarding the(TAAAA)n polymorphism in the SHBG gene and 14 studies regarding the(CAG)n polymorphism in the AR gene met our criteria. Odd ratio(OR) and weighted mean difference(WMD) were selected as the effect size measurements to evaluate the influence of the(TAAAA)n polymorphism and(CAG)n variants on PCOS risk. Begg's test was used for the evaluation of publication bias.RESULTS: With respect to the relationship between the(TAAAA)n polymorphism and PCOS risk, the statistical results showed that there was no significant difference between PCOS patients and controls in the alleles of TAAAA(S: OR = 0.91, 95%CI: 0.78-1.05; L: OR = 1.10, 95%CI: 0.95-1.27). Subgroup analyses of the combination of alleles indicated similar results(shortshort: OR = 0.87, 95%CI: 0.66-1.14; short-long: OR = 1.12, 95%CI: 0.86-1.46; long-long: OR = 1.03, 95%CI: 0.72-1.47). As for the relationship between the(CAG)n polymorphism and PCOS risk, we found no association between CAG repeat variants and PCOS risk(WDM = 0.03, 95%CI:-0.13-0.08). Subgroup analyses by race and diagnosis criteria indicated the same results(Asian: WMD =-0.03, 95%CI:-0.14-0.07; Caucasian: WMD =-0.02, 95%CI:-0.24-0.21; the criteria of Rotterdam: WMD = 0.01, 95%CI:-0.01-0.03). CONCLUSION: There is no association between(TAAAA)n polymorphism in SHBG gene,(CAG)n repeat variants in AR gene and PCOS.
